
Lucia Lopalco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9006136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Control of HIV despite the Discontinuation of Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1683-1683.	13.9	305
2	Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges. Immunity, 2011, 34, 269-280.	6.6	276
3	Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood, 2006, 108, 1580-1587.	0.6	255
4	Mucosal and Plasma IgA from HIV-1-Exposed Uninfected Individuals Inhibit HIV-1 Transcytosis Across Human Epithelial Cells. Journal of Immunology, 2000, 165, 5170-5176.	0.4	239
5	Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. Aids, 2000, 14, 1917-1920.	1.0	174
6	HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis. Mucosal Immunology, 2009, 2, 412-426.	2.7	140
7	Human Immunodeficiency Virus (HIV)–Specific IgA and HIV Neutralizing Activity in the Serum of Exposed Seronegative Partners of HIV eropositive Persons. Journal of Infectious Diseases, 1999, 180, 871-875.	1.9	135
8	Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. Aids, 2005, 19, 1947-1955.	1.0	132
9	Cross-Clade HIV-1–Specific Neutralizing IgA in Mucosal and Systemic Compartments of HIV-1–Exposed, Persistently Seronegative Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 30, 413-420.	0.9	118
10	Isotype modulates epitope specificity, affinity, and antiviral activities of anti–HIV-1 human broadly neutralizing 2F5 antibody. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12680-12685.	3.3	115
11	CCR5-Reactive Antibodies in Seronegative Partners of HIV-Seropositive Individuals Down-Modulate Surface CCR5 In Vivo and Neutralize the Infectivity of R5 Strains of HIV-1 In Vitro. Journal of Immunology, 2000, 164, 3426-3433.	0.4	114
12	Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Aids, 2000, 14, 2083-2092.	1.0	112
13	Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains Journal of Experimental Medicine, 1991, 174, 53-62.	4.2	109
14	CCR5: From Natural Resistance to a New Anti-HIV Strategy. Viruses, 2010, 2, 574-600.	1.5	108
15	The â€~immunologic advantage' of HIV-exposed seronegative individuals. Aids, 2009, 23, 161-175.	1.0	106
16	Conserved Structural Features in the Interaction Between Retroviral Surface and Transmembrane Glycoproteins?. AIDS Research and Human Retroviruses, 1992, 8, 1571-1580.	0.5	105
17	Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. Aids, 2001, 15, 431-432.	1.0	95
18	Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art. Frontiers in Immunology, 2020, 11, 1049.	2.2	88

#	Article	IF	CITATIONS
19	Apolipoprotein B mRNA–Editing Enzyme, Catalytic Polypeptide–Like 3G: A Possible Role in the Resistance to HIV of HIVâ€Exposed Seronegative Individuals. Journal of Infectious Diseases, 2007, 195, 960-964.	1.9	87
20	Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1. Blood, 2012, 119, 6259-6267.	0.6	83
21	Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cellular and Molecular Life Sciences, 2019, 76, 4869-4886.	2.4	81
22	Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. Aids, 2003, 17, 531-539.	1.0	80
23	Serum IgA of HIV-exposed uninfected individuals inhibit HIV through recognition of a region within the α-helix of gp41. Aids, 2002, 16, 1731-1741.	1.0	75
24	Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes. PLoS ONE, 2013, 8, e55438.	1.1	69
25	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood, 2006, 107, 4825-4833.	0.6	66
26	Human immunodeficiency virus type 1 gp120 C5 region mimics the HLA class I α1 peptide-binding domain. European Journal of Immunology, 1993, 23, 2016-2021.	1.6	62
27	Immunological Profile of Heterosexual Highly HIVâ€Exposed Uninfected Individuals: Predominant Role of CD4 and CD8 Tâ€Cell Activation. Journal of Infectious Diseases, 2007, 196, 1191-1201.	1.9	46
28	Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women. AIDS Research and Human Retroviruses, 2011, 27, 469-486.	0.5	46
29	A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions. Aids, 2003, 17, 43-51.	1.0	45
30	Anti-Cell Antibodies in Exposed Seronegative Individuals with HIV Type 1-Neutralizing Activity. AIDS Research and Human Retroviruses, 2000, 16, 109-115.	0.5	42
31	Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. Journal of General Virology, 2005, 86, 339-348.	1.3	42
32	Upregulation of Interferon-?? and RANTES in the Cervix of HIV-1-Seronegative Women With High-Risk Behavior. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 137-143.	0.9	40
33	SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naÃ ⁻ ve and previously COVID-19-infected individuals. EBioMedicine, 2022, 77, 103888.	2.7	39
34	HIV-Specific Antibodies But Not T-Cell Responses Are Associated With Protection in Seronegative Partners of HIV-1-Infected Individuals in Cambodia. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 412-419.	0.9	38
35	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine, 2011, 29, 4903-4912.	1.7	38
36	CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood, 2004, 104, 2205-2206.	0.6	37

#	Article	IF	CITATIONS
37	Identification of Human Immunodeficiency Virus Type 1 Glycoprotein gp120/gp41 Interacting Sites by the Idiotypic Mimicry of Two Monoclonal Antibodies. AIDS Research and Human Retroviruses, 1993, 9, 33-39.	0.5	36
38	Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. Aids, 2007, 21, 13-22.	1.0	36
39	Human Antibodies to Immunodominant C5 Region of HIV-1 gp120 Cross-React with HLA Class I on Activated Cells. AIDS Research and Human Retroviruses, 1994, 10, 157-162.	0.5	34
40	High-efficiency antibody discovery achieved with multiplexed microscopy. Microscopy (Oxford,) Tj ETQq0 0 0 rgBT	Överlock	10 Tf 50 62
41	Abundant and Superficial Expression of C-Type Lectin Receptors in Ectocervix of Women at Risk of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 239-247.	0.9	33
42	The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection. Frontiers in Immunology, 2017, 8, 1358.	2.2	33
43	Passively Transmitted gp41 Antibodies in Babies Born from HIV-1 Subtype C-Seropositive Women: Correlation between Fine Specificity and Protection. Journal of Virology, 2012, 86, 4129-4138.	1.5	32
44	Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. Virology, 2012, 431, 1-11.	1.1	32
45	Frequency and phenotype of B cell subpopulations in young and aged HIV-1 infected patients receiving ART. Retrovirology, 2014, 11, 76.	0.9	32
46	Cross-Reactive Response to Human Immunodeficiency Virus Type 1 (HIV-l) gp120 and HLA Class I Heavy Chains Induced by Receipt of HIV-1-Derived Envelope Vaccines. Journal of Infectious Diseases, 1993, 168, 1396-1403.	1.9	30
47	Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses. HIV Clinical Trials, 2002, 3, 115-124.	2.0	30
48	Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy. Journal of Virology, 2005, 79, 6848-6858.	1.5	30
49	Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology, 2013, 10, 71.	0.9	30
50	Autoantibodies to CD4 in HIV Type 1-Exposed Seronegative Individuals. AIDS Research and Human Retroviruses, 1996, 12, 273-280.	0.5	29
51	HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. Immunology Letters, 1996, 51, 39-43.	1.1	28
52	Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. Aids, 2002, 16, 1003-1008.	1.0	26
53	Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Immunology, 2007, 123, 070720050330001-???.	2.0	26
54	Calcitonin gene–related peptide inhibits Langerhans cell–mediated HIV-1 transmission. Journal of	4.2	25

Experimental Medicine, 2013, 210, 2161-2170.

#	Article	IF	CITATIONS
55	Can Natural Polyphenols Help in Reducing Cytokine Storm in COVID-19 Patients?. Molecules, 2020, 25, 5888.	1.7	25
56	Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?. Current HIV Research, 2004, 2, 127-139.	0.2	24
57	Is Autoimmunity a Component of Natural Immunity to HIV?. Current HIV Research, 2006, 4, 177-190.	0.2	23
58	Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. Aids, 2010, 24, 35-43.	1.0	23
59	HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. Journal of Biological Regulators and Homeostatic Agents, 2000, 14, 15-21.	0.7	23
60	Role of CD4 and CCR5 Levels in the Susceptibility of Primary Macrophages to Infection by CCR5-Dependent HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 1999, 15, 983-987.	0.5	22
61	Anti-CD4 Antibodies in Exposed Seronegative Adults and in Newborns of HIV Type 1-Seropositive Mothers: A Follow-up Study. AIDS Research and Human Retroviruses, 1999, 15, 1079-1085.	0.5	21
62	Two Amino Acid Substitutions within the First External Loop of CCR5 Induce Human Immunodeficiency Virus-Blocking Antibodies in Mice and Chickens. Journal of Virology, 2008, 82, 4125-4134.	1.5	19
63	Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naÃ ⁻ ve. Communications Medicine, 2021, 1, .	1.9	18
64	The role of ILâ€1β in reduced ILâ€7 production by stromal and epithelial cells: a model for impaired Tâ€cell numbers in the gut during HIVâ€1 infection. Journal of Internal Medicine, 2010, 268, 181-193.	2.7	15
65	Natural anti-CCR5 antibodies in HIV-infection and -exposure. Journal of Translational Medicine, 2011, 9, S4.	1.8	15
66	Human Immunodeficiency Virus Type 1 Glycoprotein 120-Specific T Lymphocytes Provide Intermolecular Help for Anti-CD4 Autoantibody Production in Exposed Uninfected Subjects. AIDS Research and Human Retroviruses, 1997, 13, 1461-1469.	0.5	14
67	Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones. Journal of Translational Medicine, 2014, 12, 346.	1.8	14
68	Setting of Methods for Analysis of Mucosal Antibodies in Seminal and Vaginal Fluids of HIV Seropositive Subjects from Cambodian and Italian Cohorts. PLoS ONE, 2010, 5, e9920.	1.1	13
69	Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms. Journal of Translational Medicine, 2014, 12, 335.	1.8	13
70	Relationship between serum IL-7 concentrations and lymphopenia upon different levels of HIV immune control. Aids, 2007, 21, 1048-1050.	1.0	12
71	Induction of HIV-Blocking Anti-CCR5 IgA in Peyers's Patches without Histopathological Alterations. Journal of Virology, 2014, 88, 3623-3635.	1.5	12
72	ERK1-Based Pathway as a New Selective Mechanism To Modulate CCR5 with Natural Antibodies. Journal of Immunology, 2015, 195, 3045-3057.	0.4	12

#	Article	IF	CITATIONS
73	Class B \hat{l}^2 -arrestin2-dependent CCR5 signalosome retention with natural antibodies to CCR5. Scientific Reports, 2016, 6, 39382.	1.6	12
74	M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Scientific Reports, 2017, 7, 41018.	1.6	9
75	A Nonparametric Procedure for Defining a New Humoral Immunologic Profile in a Pilot Study on HIV Infected Patients. PLoS ONE, 2013, 8, e58768.	1.1	9
76	Protecting the initial site of viral entry: an alternative HIV vaccine target. Expert Review of Vaccines, 2011, 10, 1253-1256.	2.0	7
77	Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside. Vaccines, 2020, 8, 41.	2.1	7
78	Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4. PLoS ONE, 2011, 6, e22081.	1.1	6
79	The Abrogation of Phosphorylation Plays a Relevant Role in the CCR5 Signalosome Formation with Natural Antibodies to CCR5. Viruses, 2018, 10, 9.	1.5	6
80	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. Journal of Translational Medicine, 2009, 7, 101.	1.8	5
81	HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes. Journal of General Virology, 2010, 91, 235-241.	1.3	5
82	GM-3 Lactone Mimetic Interacts with CD4 and HIV-1 Env Proteins, Hampering HIV-1 Infection without Inducing a Histopathological Alteration. ACS Infectious Diseases, 2016, 2, 564-571.	1.8	5
83	Dysfunctions in the migratory phenotype and properties of circulating immature transitional B cells during HIV-1 infection. Aids, 2016, 30, 2169-2177.	1.0	5
84	Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity. MedChemComm, 2017, 8, 422-433.	3.5	5
85	HIV-1 and the self-nonself connection: how to sleep with the enemy and be much better off. AIDS Reviews, 2008, 10, 162-71.	0.5	4
86	Native CGRP Neuropeptide and Its Stable Analogue SAX, But Not CGRP Peptide Fragments, Inhibit Mucosal HIV-1 Transmission. Frontiers in Immunology, 2021, 12, 785072.	2.2	4
87	Modeling and Spectroscopic Studies of Synthetic Diazabicyclo Analogs of the HIVâ€I Inhibitor BMSâ€378806 and Evaluation of Their Antiviral Activity. European Journal of Organic Chemistry, 2011, 2011, 287-294.	1.2	3
88	Short Communication: Decreased Plasma Calcitonin Gene-Related Peptide as a Novel Biomarker for HIV-1 Disease Progression. AIDS Research and Human Retroviruses, 2019, 35, 52-55.	0.5	3
89	Autoantibodies against beta 2-microglobulin-free HLA antigens in AIDS patients. Journal of Acquired Immune Deficiency Syndromes, 1993, 6, 1114-9.	1.0	3
90	Title is missing!. Retrovirology, 2006, 3, P36.	0.9	2

6

#	Article	IF	CITATIONS
91	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
92	Induction of Antihuman C–C Chemokine Receptor Type 5 Antibodies by a Bovine Herpesvirus Type-4 Based Vector. Frontiers in Immunology, 2017, 8, 1402.	2.2	2
93	Studies on propylamine transfer activity in anti-AdoDATO antibodies. Amino Acids, 1997, 12, 299-308.	1.2	1
94	Tackling HIV: Genetic vs. Immune CCR5 targeting. Journal of AIDS & Clinical Research, 2014, 05, .	0.5	1
95	Immunotherapy with Cell-Based Biological Drugs to Cure HIV-1 Infection. Cells, 2022, 11, 77.	1.8	1